UNASSIGNED: e18075 Background: @entity470 ( @entity470 ) mutations are common in NSCLC and they are predictive in @entity470 @entity4149 kinase inhibitor treatment. @entity984 mutation is associated with poor prognosis in NSCLC, however role of @entity817 mutation is not so clear. The aim of the study was to evaluate @entity470 (exon 19 deletion, exon 21 @entity9512 point mutation), @entity984 and @entity817 mutation rates besides their relationship with survival and response to the treatment. METHODS: We evaluated 513 NSCLC @entity1 followed-up between January 2004 and November 2009 according to our registration data, retrospectively. Only 42 advanced stage NSCLC @entity1 had enough @entity5 tissue material in paraffin blocks for all mutation analysis. These 42 advanced stage NSCLC @entity1 were enrolled to the study. They were evaluated for clinicopathological features, @entity470 , @entity984 and @entity817 mutations, @entity3866 treatment, @entity1054 ( @entity1054 ) and @entity1349 ( @entity1349 ). RESULTS: Mutation rates were as 7.14% for @entity470 exon 19 deletion; 4.76% for @entity984 codon 61 deletion and 2.38% for @entity817 @entity8554 mutation. Median folow-up was 26 months (5-83) for all @entity1 . It was 43 months (23-83) for the @entity1 who had @entity3866 and 23 months (5-61) for those who did not. Ten (23.8%) patents had @entity3866 . Two @entity1 had @entity470 exon 19 deletion and one @entity1 had @entity984 mutation among these @entity1 . They had neither @entity470 exon 21 point mutation nor different mutations together. There was significant survival difference between the @entity1 taking @entity3866 and the others (28 + 3 months versus 15 + 4 months, p=0.05). @entity1054 and @entity1349 were longer in the @entity1 who had mutations, however the difference was not significant (p=0.119 and p=0.06). CONCLUSIONS: This is the first study evaluating @entity470 , @entity984 and @entity817 mutations in advanced stage NSCLC in our country. Survival of the @entity1 who had @entity3866 was longer.

The relationship between common XXXX , @entity817 , @entity984 mutations, and prognosis in advanced-stage NSCLC with response to the treatment.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity470 :: ('1956', 'Gene') :: ['Epidermal growth factor receptor', 'EGFR'] @entity984 :: ('3845', 'Gene') :: ['K-ras', 'k-ras'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity9512 :: ('p|SUB|L|858|R', 'ProteinMutation') :: ['L858R'] @entity8554 :: ('p|SUB|V|600|E', 'ProteinMutation') :: ['V600E'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity817 :: ('673', 'Gene') :: ['braf', 'b-raf'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity470 :: (1956,Gene) :: ['EGFR']
